top
Search terms
Results 1 - 6 of 6 - ordered by :
Escardio

In the phase IIB study, serelaxin was safe and well tolerated, with positive clinical outcome symptoms and signals in patients with acute heart failure. There was, however, an improvement in ...

Date : 28/04/2017
Escardio

Data accumulated over the last 10 years strongly suggests that the risk of HF increases with the severity of abnormality of blood glucose, with an approximately linear relation between metabolic ...

Date : 02/05/2018
Escardio

The findings were clear, but unexpected. “Since plaque erosion or rupture, thromboembolism, spontaneous coronary dissection and microvascular disorders are commonly encountered in MINOCA ...

Date : 01/09/2019
Escardio

Serelaxin has failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late breaking results presented for the first time today at Heart Failure 2017 and the 4th World ...

Date : 29/04/2017
Escardio

Sunday 31 August: A new phase III study evaluating the investigational agent darapladib in patients with an acute coronary syndrome (heart attack or unstable angina) has failed to show a reduction in ...

Date : 31/08/2014
Escardio

Dr. Esquirol said, “When we analysed the data using a Kaplan-Meier survival curve, we found a significantly higher cumulative incidence of death over time in the individuals given a wrinkle ...

Date : 26/08/2018